<DOC>
	<DOCNO>NCT02192788</DOCNO>
	<brief_summary>This study aim probe effect SBRT treatment oligometastases prostate cancer , regardless basal treatment receive , I know response , biochemical control , progression-free survival well impact quality life . Primary Objective : Local symptomatic oligometastases Control prostate cancer treat SBRT . Secondary Objectives : Analyzing biochemical progression rate , progression-free survival , chemotherapy-free survival overall survival . Analyze toxicities quality life patient treatment</brief_summary>
	<brief_title>Phase II Study SBRT Treatment Oligometastases Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients histologically confirm prostate cancer , currently oligometastases / oligorrecurrencia primary treatment disease . Aged â‰¥ 18 year Time biochemical recurrence 1 year PSA doubling time &gt; 3 month Less 5 bone metastasis location ( include spinal ) lymph node . Without metastasis recurrence Choline PET / NMR Diffusion Length . Signed date write informed consent form . Patients currently treatment abiraterone , enzalutamide , chemotherapy , immunotherapy radioisotope . Patients unwilling unable comply protocol requirement schedule visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SBRT</keyword>
	<keyword>Oligometastases</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>